Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29030984 | 0.89 | HTR2C (0.49) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12873783 | 0.82 | HTR2C (0.51) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4086500 | 0.82 | KMT2A (0.44) | ESR2 | |
| SCHEMBL1200003 | 0.82 | HTR2C (0.51) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27086634 | 0.81 | SMN1; SMN2 (0.55) | F13A1TGM2TGM1SMN1; SMN2NPC1 | |
| SCHEMBL13791959 | 0.81 | HTR2C (0.49) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21960132 | 0.80 | HTR2C (0.53) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31346956 | 0.80 | HTR2C (0.53) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17317915 | 0.80 | ESR2 (0.44) | CHRM1CHRM4CHRM5ESR2SMN1; SMN2 | |
| SCHEMBL25125018 | 0.79 | HTR2C (0.61) | HTR2CAGTR2SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | HTR2C 507/4885CHRM1 1860/4885CHRM4 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.